How CEOs optimise their sleep routine
As CEO of Uber Technologies, Dara Khosrowshahi operates in a world with an abundance of screentime; unsurprisingly, that used to be part of his resting regimen. 'I used to wear a smart health tracker that rated my sleep, and I absolutely loved it,' he says. 'As someone who is really into data, getting detailed insights was right up my alley.' But eventually, he says, 'I got a little too into it, competing with myself every night'. These days, he employs a completely different sleep hack. 'I've gone back to falling asleep the old-fashioned way – no tracking, just reading.' His advice? 'Get rid of the screens, and you'll be ahead of the game.'
Thirty years ago, Sam Calagione helped kick off America's craft beer obsession when he started Dogfish Head Craft Brewery in Rehoboth Beach, in the US state of Delaware. (In 2019, the Boston Beer Company acquired it for US$300 million.) Calagione works out for 60 minutes every day, in part to be properly worn out at night. As it happens, he says, 'our best-selling beer is called 60 Minute IPA'. But his real sleep tip is to relax before bed. 'I take a half-hour bath every evening, below a giant photograph of Andre 3000 playing a flute. It calms me as I read, but it freaks my wife, Mariah, out a bit, which may be why we have separate bathrooms,' he says.
'I've been lucky in that I've always been able to sleep, despite my 20 espressos a day,' jokes Konstantin Sidorov, CEO of the London Technology Club, a UK-based venture capital fund. (It's most recent launch, in May, was the US$250 million VC Secondary Fund.) 'I typically have a late, sociable dinner with fine wine, which I'm sure helps.' On the opposite end of the spectrum, another of his sleep secrets is staying active. 'No matter how busy my schedule is, I always work out at least twice a week – wherever I am in the world.' Sidorov also takes advantage of his hectic travel schedule to nap: 'I have no problem sleeping on a plane, travelling to and from our investor hubs in Hong Kong and Dubai.'
In 2024, Rayni Williams, CEO and co-founder of The Beverly Hills Estates, closed over US$1.3 billion in house sales; her clients include actors Jeremy Renner and Angelina Jolie, and developer Bruce Makowsky. Sleep is non-negotiable, she says, and she's developed a very specific routine to help her maximise it. 'I take magnesium, zinc and ATP (a cellular energy supplement), along with a cortisol balancer to help regulate stress levels.' And that's just the start. 'A relaxing shower, followed by a full skincare and self-care regimen, helps signal to my body that it's time to rest,' she says. 'I'll often journal to clear my mind and always incorporate deep breathing work to centre myself before bed. A few nights a week, I use my Shani Darden red-light mask. This helps boost collagen; it only needs 15 minutes, so I will do a meditation simultaneously.'
Tony Tjan is the CEO of MiniLuxe, a national nail-care brand that offers nail and body services and non-toxic products; it brought in over US$26 million in revenue in 2024. Sleep is not Tjan's speciality, but he says he's been trying to be better. 'The biggest shift has been a routine that includes a micro session of meditation with a sound bowl,' he says. 'Then, earlier to bed and super early to rise. I'll never forget a saying that Tom Brady once shared with me: 'You can't be soaring with the eagles in the morning if you are hooting with owls late at night!''
A NEWSLETTER FOR YOU
Friday, 2 pm Lifestyle
Our picks of the latest dining, travel and leisure options to treat yourself.
Sign Up
Sign Up
The Carlsberg Group has been brewing beer in Copenhagen since the 1840s. Two years ago, Jacob Aarup-Andersen took over as CEO of Carlsberg, whose 2024 reported earnings hit almost US$11 billion. One of his current priorities is expanding the company's non-alcoholic beer portfolio, which complements his own personal focus on health: 'If I wake up earlier than planned, I don't fight it. I get up and get going. Trying to squeeze in more sleep often leaves me groggy and throws off my rhythm for days.' Instead, he says, 'I use that extra time to work out or run, which helps me reset and sleep deeply the following nights. It's about listening to your body.'
'This might sound counterproductive, but my best hack for a good night's sleep is to make time for a nap – at least 40 minutes a day,' says Michael Kirban. He's the co-founder and executive chairman of the Vita Coco Company, a popular coconut water brand. In 2024, Vita Coco hit US$516 million in sales of its boxed beverages. About naps, Kirban continues: 'They help me turn my brain off more easily when I go to bed at night.'
Peter McGuinness knows his way around major food companies. In 2022 he became CEO of the plant-based meat company Impossible Foods, following a run as president of popular yoghurt company Chobani. What he's not so good at is optimising sleep. 'That's not a good thing to brag about,' he says. 'I'm not philosophically against sleep. I just don't do a good job.' Part of the reason, he says, is his busy travel schedule, which has him navigating time changes: 'I'm on a plane a lot. It's enough to be disruptive and throw your biorhythms off.' McGuinness has also learned to function without a lot of sleep. 'I just kind of power through it. But I'm not too old to learn. So I will make it a priority, or more of a priority.'
Amina Belouizdad Porter is CEO of PS, which stands for Private Suite, and operates private terminals at both LAX and ATL that let clients go through private security systems before being escorted to planes. Even as she expands her company nationally, Porter prioritises her downtime. 'We've finally moved past bragging about no sleep. I aim for a consistent seven to eight hours every night. It's non-negotiable.' BLOOMBERG
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
2 days ago
- Straits Times
China reports record wave of mosquito-borne chikungunya virus
Find out what's new on ST website and app. BEIJING – A city in China's southern industrial hub has recorded 3,195 chikungunya cases so far in July, the country's biggest outbreak of the mosquito-borne virus since it first emerged in the mainland nearly two decades ago. Foshan city – in Guangdong Province, just north of Hong Kong – first reported an imported chikungunya case earlier in July, China's national broadcaster CCTV said, citing briefings from the local authorities. Infections have soared by more than 2,700 in the past week alone. While Chinese health officials have yet to explain what's behind the outbreak, Guangdong has launched stricter anti-mosquito measures, including urging residents to clear stagnant water and make sure drainage channels remain unobstructed. Chikungunya, first identified in 1952 in Tanzania, is transmitted to humans by infected mosquitoes, the World Health Organisation says. The virus causes fever and severe joint pain, and other symptoms can include headaches, muscle pain, vomiting and fatigue. The outbreak in Guangdong, an often hot and humid area of southern China, is the latest sign that tropical diseases – from dengue to malaria and zika – are expanding their reach, as climate change lets mosquitoes live in new territories that have become warmer and wetter. Increased international travel and low population immunity are also helping the spread. An explosion in cases in the Indian Ocean since the start of 2025 has sparked concerns of a spread to other countries, leading the WHO to issue an urgent call to action this week, Reuters reported. France and Italy, thousands of miles from the region, have both found locally-acquired chikungunya cases this year. 'The surge in chikungunya cases is likely due to favourable climatic conditions that allow blooms of the Aedes mosquito population,' said Dr Robert Jones, Assistant Professor in the Department of Disease Control at the London School of Hygiene & Tropical Medicine. 'These are aggressive, day-biting mosquitoes that thrive in warm, wet conditions.' More than five billion people live in areas across 119 countries at risk from chikungunya, the WHO told reporters in Geneva, Reuters said. Some 220,000 cases and 80 related deaths have been reported in 14 countries and territories globally so far in 2025, according to the European Centre for Disease Prevention and Control. China recorded its first chikungunya case in 2008, an imported infection detected at an airport in Guangdong. The first locally transmitted cases – infecting 253 people – were reported in the province two years later. Since then, only sporadic cases have been found, in Yunnan and Fujian provinces. Globally, population susceptibility is likely elevated in areas where chikungunya outbreaks haven't tended to occur, said Ms Patricia Gallego Delgado, Associate Director at London-based disease forecasting firm Airfinity. The wave is 'attributable to lower levels of population immunity, as individuals in these regions may have had limited or no prior exposure to the virus,' she said. BLOOMBERG
Business Times
4 days ago
- Business Times
AstraZeneca vows to spend US$50 billion on US manufacturing, development
[MUNICH/WASHINGTON] AstraZeneca plans to invest US$50 billion in the US before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on imported medicines. The investment will go towards manufacturing as well as research and development, Astra said in a statement. It includes US$4 billion for a new facility in Virginia that will make drugs for chronic diseases, Kevin Hassett, director of the US National Economic Council, said on Monday (Jul 21) at an event in Washington, DC. 'With the completion of this investment, substantially all of AstraZeneca's pharmaceuticals sold at the United States will be produced in the United States,' Hassett said. Astra's announcement comes as European drug companies rush to highlight their significant footprints in the US in hopes of mitigating the impact of any potential tariffs from US President Donald Trump. Astra already announced plans in November, a week after Trump's election, to invest US$3.5 billion in the US by the end of 2026, noting at the time that it employs nearly 18,000 people in the country. Since then, European competitors have touted even larger spending plans. Switzerland's Novartis in April announced plans for US$23 billion in US-based infrastructure spending, while cross-town rival Roche Holding said it would invest US$50 billion. In May, French drugmaker Sanofi announced intent to invest at least US$20 billion in the US by 2030. Pascal Soriot, who's been chief executive officer of Astra since 2012, has also urged tariff restraint. This spring, he recommended that US officials exempt medicines from tariffs, arguing that tax incentives are a better way to attract investment in drug development and manufacturing. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Trump has proposed various timelines for tariffs on pharmaceuticals, most recently floating duties that would be imposed as soon as Aug 1. The president said that he expects to give companies a year to bring manufacturing to the US before imposing tariffs as high as 200 per cent. Meanwhile, Soriot has raised concerns in the UK about his commitment to the home country. He has long complained about the UK's regulatory environment, which he says is a threat to hold back the UK from staying competitive with the US and China. In January, Astra abandoned plans for a £450 million (S$777 million) vaccine manufacturing plant in Liverpool. The company operates 17 manufacturing sites in 12 US states. Earlier this month, British paper The Times reported that Soriot is considering moving the company's stock listing to the US. That would be a major blow to the UK's equity markets, which have endured similar defections from other companies in recent years. Under Soriot's leadership, Astra's market value has more than tripled as the company has become a global powerhouse in cancer medicines. It's also built up a significant drug pipeline for other areas including cardiovascular, renal and metabolic diseases. BLOOMBERG
Straits Times
5 days ago
- Straits Times
Trial of new dengue vaccine begins recruitment for child participants in Singapore
Find out what's new on ST website and app. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying (left), and Dr Zhong Youjia, another investigator on the study. SINGAPORE – A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine in children aged two to 17. Developed by US-based pharmaceutical firm MSD, V181 is a single-dose vaccine that aims to provide protection against all four serotypes, or strains, of the dengue virus. Phase three clinical trials are typically the last stage of testing before a drug's details and clinical trial results are submitted to the regulatory authorities for approval. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying, noted that V181 is a live-attenuated vaccine, which uses weakened versions of all four dengue serotypes. 'Using the weakened forms of all these four dengue serotypes stimulates a human immune response to create protection against dengue infection in future,' said Prof Chia, who also heads the National Centre for Infectious Diseases Research Office. The new study here hopes to recruit at least 700 healthy children between the ages of two and 17, including both those who have previously contracted dengue and those who have never had the disease, said Dr Zhong Youjia, another investigator on the study. This particular study focuses on children as they are more vulnerable to dengue and are also at a greater risk of severe infection, said the associate consultant at National University Hospital's (NUH) Khoo Teck Puat – National University Children's Medical Institute. Side effects from the vaccine have been mild and short-lived, said Prof Chia, noting that they include muscle aches and fatigue. Children enrolled in the study will be randomly chosen to get a single shot of either the vaccine or a placebo. 'There have been no serious adverse events linked to vaccination with V181 to date, and the previous trials actually have shown a very good and favourable safety profile,' Prof Chia said. In Singapore, the study is being conducted at NUH and Tan Tock Seng Hospital, which have already started recruiting participants. Only a handful of children have been recruited so far for the study here, which began in June, said Dr Zhong. A third recruitment site, KK Women's and Children's Hospital, is also in the works. As at July 12, there have been 2,816 dengue cases recorded here in 2025, according to figures from the National Environment Agency (NEA). In May, NEA noted that the number of dengue cases recorded here between January and May 2025 has dropped by about 74 per cent from the same period in 2024. Worldwide, the study aims to enrol about 12,000 healthy children, also between the ages of two and 17, who will receive either a single dose of V181 or a placebo. It aims to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific, including Indonesia, Malaysia and the Philippines. Developing effective dengue vaccines has been difficult as the four serotypes are effectively four different viruses, said Prof Chia. While getting infected by one serotype grants lifelong protection against that particular strain, it provides only short-term protection against the other three, she said. This short-term protection eventually wanes, she noted, adding that those who contract dengue more than once risk antibody-dependent enhancement – a phenomenon where antibodies that are generated due to a vaccine or prior infection actually increase the severity of an infection. Dr Zhong noted this can result in dengue shock syndrome, otherwise known as dengue haemorrhagic fever, a potentially life-threatening complication with symptoms including circulatory failure. Designing a dengue vaccine has been challenging as it has to take into account this phenomenon, Prof Chia said. Should the trials be successful and the vaccine meet regulatory requirements, V181 could be commercially available as early as within the next three to five years, said Dr Zhong. Dr Paula Annunziato, senior vice-president for infectious diseases and vaccines global clinical development at MSD Research Laboratories, noted that half the world's population live in areas at risk for dengue. 'If successful, V181 could provide an important single-dose option for at-risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe,' she said. Dengvaxia, developed by Sanofi Pasteur, is currently the only dengue vaccine approved for use in Singapore. However, it is available only for those between 12 and 45 years old who have previously been infected and poses an increased risk of causing severe dengue in those who have never been infected. In May 2024, another quadrivalent vaccine, Qdenga, received pre-qualification from the World Health Organisation (WHO) – a process that aims to ensure the safety and efficacy of treatments – with WHO recommending the vaccine's use for children aged between six and 16 in dengue-prone areas. Developed by Japanese pharmaceutical company Takeda, Qdenga was made available in Malaysia in June 2024 . Qdenga was submitted for approval here in 2022. However, the following year, the Health Sciences Authority said Takeda had withdrawn its application. The authority said then that the company could submit another application with further clinical data on the vaccine meeting the 'required safety, efficacy and quality standards for use locally'.
